A Phase I/II First-in-human Trial Investigating Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Dry Powder Cisplatin Formulation for Inhalation to Treat Stage IV Non-small Cell Lung Cancer Patients
Latest Information Update: 29 Sep 2025
At a glance
- Drugs Cisplatin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors InhaTarget Therapeutics
Most Recent Events
- 26 Mar 2025 Planned End Date changed from 30 Jun 2025 to 1 Oct 2026.
- 05 Nov 2024 New trial record